Treatment of Cavernous Sinus Aneurysms with Flow Diversion: Results in 44 Patients by R C Puffer et al.
ORIGINAL RESEARCH
INTERVENTIONAL
Treatment of Cavernous Sinus Aneurysms with Flow Diversion:
Results in 44 Patients
R.C. Puffer, M. Piano, G. Lanzino, L. Valvassori, D.F. Kallmes, L. Quilici, H.J. Cloft, and E. Boccardi
ABSTRACT
BACKGROUND AND PURPOSE: Aneurysms of the cavernous segment of the ICA are difficult to treat with standard endovascular
techniques, and ICA sacrifice achieves a high rate of occlusion but carries an elevated level of surgical complications and risk of de novo
aneurysm formation. We report rates of occlusion and treatment-related data in 44 patients with cavernous sinus aneurysms treated with
flow diversion.
MATERIALS AND METHODS: Patients with cavernous segment aneurysms treated with flow diversion were selected from a prospec-
tively maintained data base of patients from 2009 to the present. Demographic information, treatment indications, number/type of flow
diverters placed, outcome, complications (technical or clinical), and clinical/imaging follow-up data were analyzed.
RESULTS: We identified 44 patients (37 females, 7 males) who had a flow diverter placed for treatment of a cavernous ICA aneurysm (mean
age, 57.2; mean aneurysm size, 20.9 mm). The mean number of devices placed per patient was 2.2. At final angiographic follow-up (mean,
10.9 months), 71% had complete occlusion, and of those with incomplete occlusion, 40% had minimal remnants (3 mm). In symptomatic
patients, complete resolution or significant improvement in symptoms was noted in 90% at follow-up. Technical complications (which
included, among others, vessel perforation in 4 patients, groin hematoma in 2, and asymptomatic carotid occlusion in 1) occurred in
approximately 36% of patients but did not result in any clinical sequelae immediately or at follow-up.
CONCLUSIONS: Our series of flow-diversion treatments achieved markedly greater rates of complete occlusion than coiling, with a
safety profile that compares favorably with that of carotid sacrifice.
ABBREVIATION: PED  Pipeline Embolization Device
Aneurysms originating from the cavernous segment of the in-ternal carotid artery are thought to have a more benign nat-
ural history than intracranial aneurysms in other vascular territo-
ries, with a substantially lower risk of rupture.1-3 Treatment is
indicated when these aneurysms are symptomatic and/or reach
very large and giant size. Due to the dysplastic nature of these
aneurysms and typically difficult morphology, achieving com-
plete aneurysm occlusion by using endovascular “reconstructive”
techniques is difficult. “Deconstructive” ICA sacrifice for cavern-
ous ICA aneurysms with or without bypass achieves remarkably
high rates of complete aneurysm occlusion.4 However, ICA sac-
rifice is associated with several potential disadvantages because
many of these patients have contralateral mirror ICA aneurysms
and ipsilateral ICA occlusion limits therapeutic options for those
contralateral aneurysms in the future. Concerns have been raised
about long-term hemodynamic effects of ICA sacrifice in young
patients, with resultant de novo aneurysm formation in 4%–11%
of patients thought to result from increased flow in the anterior
and posterior communicating artery regions.5-8 Finally, the need
for either low- or high-flow bypass in patients who do not tolerate
balloon test occlusion may add risk to the overall procedure.
Endoluminal flow-diversion devices have been associated with
high rates of complete aneurysm occlusion, even in giant aneu-
rysms.9 Cavernous ICA aneurysms appear well-suited to treat-
ment by flow diversion, given the sidewall morphology and lack of
critical perforating side branches of the aneurysm in the region of
the aneurysm cavity. However, given the relatively benign natural
history of these aneurysms and the excellent results reported with
ICA sacrifice, it remains critical to assess the risk-benefit ratio for
treatment by flow diversion compared with alternative ap-
proaches. While there are multiple studies demonstrating a single
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institutional experience treating intracranial aneurysms with flow
diverters, to our knowledge, there has been no previous case series
published focusing specifically on treatment of cavernous ICA
aneurysms by flow diversion. In the current study, we detail the
safety and efficacy of flow diversion in 44 patients with cavernous
ICA aneurysms.
MATERIALS AND METHODS
This study was approved by the institutional review board at both
institutions where data were collected. From prospectively main-
tained data bases of patients treated with flow diverters, those who
underwent treatment for a cavernous ICA aneurysm from 2009 to
the present were selected and retrospectively reviewed. Some of
the patients reported were enrolled in the Pipeline for Uncoilable
or Failed Aneurysms Study9 or were reported as part of a large
series on flow diversion.10 Demographic information, indication
for treatment, type and number of flow diverters placed, treat-
ment outcome, complications (technical or clinical, with 1-sided
confidence intervals), and clinical/imaging follow-up data were
collected and analyzed. The 5 main operators performing these
procedures each had at least 10 years of independent practice, and
many of the procedures were performed with 2 experienced op-
erators present.
All patients undergoing treatment were premedicated with as-
pirin and clopidogrel, and full anticoagulation was maintained
during the procedure (target activated clotting time between 250
and 300 seconds). Following the procedure, patients were main-
tained on dual antiplatelet therapy for 3 months (institution 1)
and for 1 month (institution 2). After these time intervals, clopi-
dogrel was discontinued and aspirin was continued indefinitely
(institution 1) and for a total of 3 months (institution 2). No
patient underwent testing for clopidogrel response. The shorter
duration of the dual antiplatelet therapy is related to our belief
that if flow diverters are adequately sized, they oppose better
against the vessel wall; therefore, after an initial period of potential
higher thrombogenicity, the risk of late thromboembolic compli-
cations when these devices are used in the proximal ICA is very
low and is outweighed by the risk of continuing dual antiplatelet
therapy akin to a proximal carotid stent.11
All procedures were performed with the patient under general
endotracheal anesthesia. Patients were treated with a Pipeline
Embolization Device (PED; Covidien, Irvine, California), a Silk
flow-diverting stent (Balt Extrusion, Montmorency, France), a
Surpass Stent (Stryker Neurovascular, Fremont, California), or,
in some cases, a combination of 2 separate devices. There were 2
patients in the series in whom a Liberté stent (Boston Scientific,
Natick, Massachusetts) was used to correct a persistent stenosis
related to compression from the aneurysm mass; in 1 patient, a
LEO stent (Balt Extrusion) was used as a scaffold for the flow
diverter to bridge a wide aneurysm neck. Flow diverters were sized
to match the maximum diameter of the target vessel, and 1 or
multiple devices were used at the discretion of the operators to
maximize the chance of complete aneurysm occlusion and/or to
ensure adequate coverage of the aneurysm neck and of a segment
of the parent artery proximal and distal to it. Digital subtraction
angiography was performed at 2 frames per second before and
following placement of the flow diverter. Flow diverters were
placed under fluoroscopy with a frame rate of 12.5 frames per
second.
RESULTS
We identified 44 patients (37 females and 7 males) who had a flow
diverter placed for treatment of a cavernous ICA aneurysm. Their
clinical and demographic information is included in On-line Ta-
ble 1. The mean age for the cohort was 57.2  14.3 years (range,
17– 81 years), and the mean aneurysm size was 20.9  6.9 mm
(range, 4 – 40). Of note, 48% of patients (21/44) in this series had
giant cavernous sinus aneurysms (25 mm). The most frequent
presenting symptoms included cavernous cranial neuropathy/
diplopia in 52% (23/44), headache/retro-orbital pain in 30% (13/
44), and incidental discovery after an unrelated symptom with or
without interval growth in 23% (10/44). Adjacent aneurysms
were present in 27% of patients (12/44), and in 4 of the patients
with adjacent aneurysms, the flow diverter also covered the neck
of the adjacent aneurysm, resulting in treatment of multiple an-
eurysms simultaneously.
Aneurysms were previously treated with coils in only 1 patient.
The PED was the only flow diverter used in 64% of patients (27/
42), 24% (10/42) were treated with the Silk device only, 2% (1/42)
were treated with the Surpass flow diverter, and 4/42 patients
(10%) were treated with a combination of flow diverters and scaf-
fold stents placed telescopically. Multiple devices were required in
the initial procedure in 48% (20/42) of patients to achieve ade-
quate coverage of the aneurysm neck. The mean number of flow
diverters placed in this cohort was 2.2  2.0 (range, 1–10).
Adequate angiographic and clinical follow-up was available in
36 patients, and their angiographic and clinical outcomes are
demonstrated in On-line Table 2. One patient was excluded from
occlusion analysis due to subsequent transvenous coiling of the
cavernous sinus for treatment of a carotid cavernous fistula. At
final angiographic follow-up (3–36 months; mean, 10.9 months),
71% (25/35) had complete occlusion, and of the 10 patients with
incomplete occlusion, 40% (4/10) had minimal remnants present
on angiography. In patients who had incomplete occlusion noted
on 6-month angiograms and also had a follow-up angiogram at 12
months or later, 50% (4/8) were found to have progressed to
complete occlusion at final follow-up (Fig 1).
There were 29 patients who were symptomatic at presentation
and had adequate clinical follow-up. Complete resolution or sig-
nificant improvement of their presenting symptoms was noted in
90% of patients (26/29). Persistent, pre-existing symptoms in-
cluded continued cranial neuropathy in 2 patients and minor
headache in 1 patient. New clinical symptoms developed in 23%
(10/29) of patients periprocedurally, mostly 2–5 days after the
treatment, and included localized retro-orbital pain in 5, worsen-
ing of pre-existing diplopia in 3, chemosis in 2, and a complete
cavernous sinus syndrome in 1 patient with a giant cavernous
aneurysm. This periprocedural pain resolved completely within
the first month in all these patients with medical treatment (pain
medications and/or short steroid taper). The patients with wors-
ening or new-onset diplopia experienced resolution of their clin-
ical symptoms by the time of the first clinical follow-up (usually 1
month after treatment), and the patient with a delayed, complete
cavernous sinus syndrome had almost complete resolution of
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these new symptoms at 6-month follow-up but continues to have
slight upgaze limitation. A small, asymptomatic distal hematoma
in the frontal lobe was identified on postprocedural CT in 1 pa-
tient (2%, 1/42).
Intraprocedural technical complications were encountered in
36% of procedures (16/44), including minor catheter-induced
vasospasm (4.5%, 2/44), incomplete opening of the device requir-
ing angioplasty (16%, 7/44), inability to pass the catheter across
the aneurysm due to difficult anatomy (2%, 1/44), and vessel per-
foration (9%, 4/44). Access complications (groin hematoma re-
quiring repair by vascular surgery) occurred in 2 patients (4.5%).
Delayed, in-stent stenosis of 50% was found in 1 patient (2%) at
follow-up, and in this patient, a Liberté stent was later placed to
prevent progression of the stenosis. Asymptomatic ICA occlusion
was found in 1 patient (2%) at follow-up angiography. No pa-
tients who experienced intraprocedural or delayed complications
had any clinical sequelae either immediately postprocedure or at
follow-up (95% confidence interval, 0%–9.6%).
DISCUSSION
In this study, we demonstrated that flow diverters are an effective
treatment technique for cavernous aneurysms, not only for
achieving aneurysm closure but also for resolution of presenting
clinical symptoms. Remarkably high rates of complete or near-
complete occlusion were achieved (83%), even though the mean
aneurysm size was approximately 21 mm and almost 50% of the
cohort had giant aneurysms. Furthermore, 90% of cranial neu-
ropathies, either pre-existing or developing soon after treatment,
resolved with time in all except 1 patient. These findings are sim-
ilar to those in a recently published multicenter study on flow-
diversion with a subset analysis of 26 cavernous sinus aneurysms.
In that study, the authors achieved a complete or near-complete
occlusion rate of 100%, with resolution or significant improve-
ment in symptoms in 72% of patients.12 Symptom resolution in
these patients was related to decreased pulsation of the aneurysm
and to regression of the sac, which follows successful exclusion of
the aneurysm with flow diversion as eloquently demonstrated by
Szikora et al.13 Perianeurysmal inflammation can cause patients
to have initial worsening of their presenting symptoms, new-on-
set headache, or cranial neuropathy. This occurred in 23% of our
patients, and mostly resolved with time, sometimes after a short
steroid taper. Overall, these results suggest that flow diversion
should be considered a viable treatment for symptomatic, cavern-
ous ICA aneurysms in selected patients.
Traditional methods for treatment of cavernous sinus aneu-
rysms, such as carotid sacrifice with or without bypass, have been
very effective. Carotid sacrifice achieves a 98.7% rate of complete
aneurysm occlusion and an 81% resolution of diplopia but is as-
sociated with a 5% risk of procedure-related neurologic deficits.4
Furthermore, carotid sacrifice may lead to changes in the hemo-
dynamics of cerebral blood flow and increased stress on arterial
walls of the contralateral carotid circulation.7,14-20 This hemody-
namic issue is of particular importance in patients with large,
cavernous sinus aneurysms because they are often young females
who can have an intrinsic weakness of the carotid vessel wall.21 This
may predispose to the formation and growth of aneurysms contralat-
eral to carotid sacrifice (estimated incidence, 4%–11% in a previous
review5) and also may hinder treatment choices of contralateral mir-
ror aneurysms in the future. Unlike carotid sacrifice, endovascular
coiling is a “reconstructive” technique that has been used in the treat-
ment of cavernous sinus aneurysms. However, because these aneu-
rysms are often very large or giant with a wide neck, standard endo-
vascular coiling achieved a complete aneurysm occlusion rate of only
43% in a systematic review from 2002.4
Flow diversion may provide a valid alternative to these more
traditional endovascular techniques by preserving the parent ar-
tery while achieving high complete occlusion rates. A recent pub-
lication of the results from the Pipeline for Uncoilable or Failed
Aneurysms multicenter trial of flow diversion for intracranial aneu-
rysms of the ICA proximal to the origin of the posterior communi-
cating artery demonstrated an overall 5% morbidity, similar to that
in ICA sacrifice, though subset analysis of morbidity in patients
treated for cavernous ICA aneurysms was not performed.9
Another review and meta-analysis of flow diversion demon-
strated an all-comer late complication rate of 2.4%.22 Few studies
have subset analyses specific to cavernous segment aneurysms,
but in a multicenter Italian study, Briganti et al23 reported a 4%
mortality rate for treatment of cavernous segment aneurysms
with flow diverters, but this comprised 3 total cases (of 76): Two
patients experienced fatal ICA thrombosis, and the other experi-
enced a fatal ICA perforation, all during treatment of giant cav-
ernous aneurysms. The mortality rate reported in the Italian study
differs from that in both the subset analysis in the recent Canadian
study12 and in this series (both with 0% overall morbidity and
mortality, 70 total combined cavernous aneurysms).
However, despite the very low incidence of permanent neuro-
logic symptoms in patients in this series, technical complications
were not uncommon. These were mostly related to vasospasm,
incomplete device opening, and difficulty passing the catheter
FIG 1. A, Lateral digital subtraction angiography of the left ICA in a
67-year-old woman demonstrates a large (20 mm) aneurysm originat-
ing from the cavernous segment of the ICA. B, Immediate postplace-
ment image of 3 PEDs demonstrates stasis of contrast within the
aneurysm. C, Follow-up lateral DSA at 6 months demonstrates a min-
imal remnant (white arrow). D, Final angiographic follow-up demon-
strates complete aneurysm occlusion at 36 months.
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through the segment harboring the aneurysm. There were 4 in-
stances of vessel perforation while attempting to obtain adequate
catheter positioning for treatment. With further improvement of
implant construction and delivery techniques, the incidence of
these complications may decrease. Nevertheless, these issues un-
derscore the fact that many of these procedures are not always
smooth and straightforward. Keeping in mind these issues, we
have slightly modified our approach, and after a phase of probably
“overenthusiasm” for a novel technology, we now tend to be more
cautious, especially in elderly patients. For elderly patients with
challenging aneurysms, in whom issues with traversing the aneu-
rysm or excessive proximal tortuosity can be anticipated, we in-
clude balloon test occlusion at the outset of the procedure, and in
the presence of adequate collateral circulation, treatment via ICA
sacrifice may be preferred.
This study is limited by its small sample size and the fact that
multiple, different, flow-diverting stents were used, making it dif-
ficult to attribute these data to any particular device with its asso-
ciated specifications. Timelines for radiographic follow-up were
different between the 2 institutions, and not all patients in the
cohort adhered to strict radiographic follow-up schedules, so it is
difficult to determine which patients with incomplete occlusion at
final follow-up in this series will eventually demonstrate complete
occlusion. We did not perform any comparison of flow diversion
with standard endovascular coiling techniques or carotid occlu-
sion in this series; thus, we must be careful in comparing our
results with those of other independent series. The patients in this
cohort were highly selected, treated at 2 centers, both having very
extensive experience with treatment of intracranial aneurysms;
due to the relative novelty of flow diversion, the patients were
carefully followed with adequate clinical and radiographic fol-
low-up in nearly every case.
CONCLUSIONS
Flow-diverting stents represent a highly effective treatment tech-
nique for aneurysms of the cavernous ICA and may be a safer
choice than carotid sacrifice with or without surgical bypass, given
the ideal vessel characteristics of the cavernous ICA for flow di-
version. Technical issues are not uncommon, occurring in just
more than 1 in 3 cases, some of which were serious complications,
though none resulted in any permanent neurologic morbidity in
this series. Nevertheless, these technical issues, combined with the
often advanced age of these patients and their relative vessel fra-
gility, require a careful analysis to choose the procedure best in-
dicated in each individual case.
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